3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
3
Phase 2
2
Phase NA
1
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Melanoma
30
Neoplasms
11
Thyroid Neoplasms
7
Thyroid Carcinoma, Anaplastic
6
Brain Neoplasms
6
Multiple Myeloma
4
Glioma
4
Colorectal Neoplasms
4
Hematologic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Thyroid Cancer, Papillary
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Glioblastoma
2
Astrocytoma
2
Ameloblastoma
2
Adenocarcinoma, Follicular
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, follicular
1
Thyroid cancer, Hurthle cell
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Solid Tumor
1
Rectal Neoplasms
1
Rare Malignant Neoplasm
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
dabrafenib
×
Clear all
NCT04116541
2026-04-24
MegaMOST
Centre Leon Berard
Phase 2
Recruiting
455 enrolled
NCT02142036
2019-03-13
MetAction
Oslo University Hospital
Phase 2
Completed
50 enrolled